On Saturday, April 18, 2026, President Donald Trump signed an executive order (“Order”) which he proclaimed would “dramatically accelerate access to new medical research and treatments based on psychedelic drugs.” Joe Rogan was there for some reason; Trump joked about trying ibogaine, too. Trump also took the opportunity to complain that his other executive order on controlled substances—marijuana—seems
A new age for psychedelics We are on the verge of a psychedelic renaissance, with the Food and Drug Administration (FDA) accepting a new drug application for midmafetamine (MDMA) in February of this year. MDMA the active ingredient in the common party drug “ecstasy” or “molly”. If approved, the drug would be used to treat
The use of psilocybin (magic mushrooms) for therapeutic purposes gains traction Last month, the NBA and its players association reached a tentative deal that the league would no longer test players for marijuana. Indeed, the NBA is lifting its ban on marijuana in the new collective bargaining agreement. Meanwhile, the NFL and its players agreed
Among the emerging medical uses for MDMA and psilocybin is their relative dimethyltryptamine (DMT). Although a Schedule I drug in the United States, DMT increasingly is the subject of study for its potential efficacy in treating a wide array of mental-health conditions including depression, anxiety, and PTSD. Much of this research is occurring outside of
We are pleased to announce that four Harris Sliwoski attorneys have been recognized as Global Top 200 Psychedelic Lawyers and Policy & Regulatory Experts for 2023 by the Cannabis Law Report. The Cannabis Law Report compiles a directory of lawyers that it considers to be the best legal minds, whether they come from a policy,
We’re finally ready to launch. After a two-year advisory and developmental period, the Oregon Health Authority (OHA) has adopted and released final rules to implement a first-of-its-kind, regulated psychedelics program. You can find the new rules here. OHA will also begin accepting applications for psilocybin service centers, testing labs, manufacturers and facilitators next Monday, January
There’s been a lot of news about Tuesday’s election. One of the things that hasn’t made the waves is Colorado’s approval of Prop. 122, which will pave the way for psilocybin clinics like in Oregon. Prop. 122 is actually much broader than Oregon’s Measure 109, and legalizes psychedelics far beyond just psilocybin. Many expressed opposition
This will be one of the most important weeks for Oregon psilocybin to date, at least from a news and public information perspective. This is because we expect the Oregon Health Authority (OHA) to publish all remaining proposed administrative rules for the Oregon psilocybin program. The forthcoming rules should cover everything outlined in Measure 109
Friday was a great day for psychedelics. More generally, Friday was a great day for science and medicine, the rule of law and rational inquiry. This is because the DEA backed down on its clumsy attempt to ban five more psychedelic substances (tryptamines), which it had moved to place on Schedule I of the federal
The Oregon Psilocybin Advisory Board (OPAB) was established by Measure 109 and is responsible for making recommendations to the Oregon Health Authority (OHA) for psilocybin services in Oregon. OPAB has met monthly since March of 2021, and the last monthly meeting is set for June 22, 2022. After that, OPAB will meet every two months.
